The pathogenesis of chronic idiopathic urticaria

Archives of Dermatology

Volumn 133, Issue 8, 1997, Pages 1003-1008

  Sabroe, Ruth A ^a   Greaves, Malcolm W ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AUTOANTIBODY; CYCLOSPORIN; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HLA DR4 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN E RECEPTOR;

AUTOIMMUNITY; BASOPHIL; CHRONIC URTICARIA; DRUG RESISTANCE; HISTAMINE RELEASE; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MAST CELL; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW;

EID: 0030806932     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.133.8.1003     Document Type: Review

References (107)

1. Greaves MW. Chronic urticaria. N Engl J Med. 1995;332:1767-1772.
2. Juhlin L. Incidence of intolerance to food additives. Int J Dermatol. 1980;19:548-551.
3. Hellgren L. The prevalence of urticaria in the total population. Acta Allerologica. 1972;27:236-240.
4. Juhlin L. Recurrent urticaria: clinical investigation of 330 patients. Br J Dermatol. 1981;104:369-381.
5. Sibbald RG, Cheema AS, Lozinski A, Tarlo S. Chronic urticaria: evaluation of the role of physical, immunologic, and other contributory factors. Int J Dermatol. 1991;30:381-386.
6. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. Chronic urticaria: impact on quality of life. Br J Dermatol. 1997;136:197-201.
7. Champion RH, Roberts SOB, Carpenter RG, Roger JH, Urticaria and angiooedema: a review of 554 patients. Br J Dermatol. 1969;81:588-597.
8. Krause LB, Shuster S. H,-receptor-active histamine not sole cause of chronic idiopathic urticaria. Lancet. 1984;2:929-930.
9. Jorizzo JL, Smith EB. The physical urticarias: an update and review. Arch Dermatol. 1982;118:194-201.
10. Barlow RJ, Warburton F, Watson K, Black AK, Greaves MW. Diagnosis and incidence of delayed pressure urticaria in patients with chronic urticaria. J Am Acad Dermatol. 1993;29:954-958.
11. Mehregan DR, Hall MJ, Gibson LE. Urticarial vasculitis: a histopathologic and clinical review of 72 cases. J Am Acad Dermatol. 1992;26:441-448.
12. Monroe EW. Urticarial vasculitis: an updated review. J Am Acad Dermatol. 1981;5:88-95.
13. Weedon D. Urticarias. In: Weedon D, ed. The Skin. New York, NY: Churchill Livingstone Inc; 1992;9:215-219.
14. Russell Jones R, Bhogal B, Dash A, Schifferli J. Urticaria and vasculitis: a continuum of histological and immunopathological changes. Br J Dermatol. 1983;108:695-703.
15. Michaëlsson G, Juhlin L. Urticaria induced by preservatives and dye additives in food and drugs. Br J Dermatol. 1973;88:525-532.
16. Warin RP, Smith RJ. Challenge test battery in chronic urticaria. Br J Dermatol. 1976;94:401-406.
17. Inman WHW, Rawson NSB, Wilton LV, Pearce GL, Speirs CJ. Postmarketing surveillance of enalapril, I: results of prescription-event monitoring. BMJ. 1988;297:826-829.
18. Cameron HA, Higgins TJC. Clinical experience with lisinopril: observations on safety and tolerability. J Hum Hypertens. 1989;3:177-186.
19. Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA. 1988;260:967- 970.
20. Niimi N, Francis DM, Kermani F, et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol. 1996;106:1001-1006.
21. Mekori YA, Giorno RC, Anderson P, Kohler PF. Lymphocyte subpopulations in the skin of patients with chronic urticaria. J Allergy Clin Immunol. 1983;72:681-684.
22. Elias J, Boss E, Kaplan AP. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol. 1986;78:914-918.
23. Natbony SF, Phillips ME, Elias JM, Godfrey HP, Kaplan AP. Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol. 1983;71:177-183.
24. Smith CH, Kepley C, Schwartz LB, Lee TH. Mast cell number and phenotype in chronic idiopathic urticaria. J Allergy Clin Immunol. 1995;96:360-364.
25. Barlow RJ, Ross EL, MacDonald DM, Kobza-Black A, Greaves MW. Mast cells and T lymphocytes in chronic urticaria. Clin Exp Allergy. 1995;25:317-322.
26. Peters MS, Schroeter AL, Kephart GM, Gleich GJ. Localization of eosinophil granule major basic protein in chronic urticaria. J Invest Dermatol. 1983;81:39-43.
27. Peters MS, Winkelmann RK. Neutrophilic urticaria. Br J Dermatol. 1985;113:25-30.
28. Winkelmann RK, Reizner GT. Diffuse dermal neutrophilia in urticaria. Hum Pathol. 1988;19:389-393.
29. Winkelmann RK, Wilson-Jones E, Smith NP, English JSC, Greaves MW. Neutrophilic urticaria. Acta Derm Venereol (Stockh). 1988;68:129-133.
30. Sodhi N, Peterson EA, Schroeter AL, et al. Inflammatory cells in chronic urticaria. J Allergy Clin Immunol. 1990;85:204.
31. Dolovich J, Hargreave FE, Chalmers R, Shier KJ, Gauldie J, Bienenstock J. Late cutaneous allergic responses in isolated IgE-dependent reactions. J Allergy Clin Immunol. 1973;52:38-46.
32. Solley GO, Gleich GJ, Jordon RE, Schroeter AL. The late phase of the immediate wheal and flare skin reaction: its dependence upon IgE antibodies. J Clin Invest. 1976;58:408-420.
33. Charlesworth EN, Hood AF, Soter MA, Kagey-Sobotka A, Norman PS, Lichtenstein LM. Cutaneous late-phase response to allergen: mediator release and inflammatory cell infiltration. J Clin Invest. 1989;83:1519-1526.
34. + cellular infiltrate associated with allergen-induced late-phase skin reactions in atopic subjects. Clin Exp Immunol. 1991;84:270-274.
35. Leiferman KM, Fujisawa T, Gray BH, Gleich GJ. Extracellular deposition of eosinophil and neutrophil granule proteins in the IgE-mediated cutaneous late phase reaction. Lab Invest. 1990;62:579-589.
36. Tsicopoulos A, Hamid Q, Haczku A, et al. Kinetics of cell infiltration and cytokine messenger RNA expression after intradermal challenge with allergen and tuberculin in the same atopic individuals. J Allergy Clin Immunol. 1994;94:767- 772.
37. Nicod LP, Cytokines, I: overview. Thorax. 1993;48:660-667.
38. 2-receptor blocking agent. Br J Clin Pharmacol. 1977;4:367-369.
39. Robertson I, Greaves MW. Responses of human skin blood vessels to synthetic histamine analogues. Br J Clin Pharmacol. 1978;5:319-322.
40. Foreman JC. Neuropeptides and the pathogenesis of allergy. Allergy. 1987;42:1-11.
41. Davies MG, Greaves MW. Sensory responses of human skin to synthetic histamine analogues and histamine. Br J Clin Pharmacol. 1980;9:461-465.
42. Kubes P, Kanwar S. Histamine induces leukocyte rolling in post-capillary venules; a P-selectin-mediated event. J Immunol. 1994;152:3570-3576.
43. Greaves MW, Sondergaard J. Urticaria pigmentosa and factitious urticaria: direct evidence for release of histamine and other smooth muscle-contracting agents in dermographic skin. Arch Dermatol. 1970;101:418-425.
44. Kaplan AP, Horáková Z, Katz SI. Assessment of tissue fluid histamine levels in patients with urticaria. J Allergy Clin Immunol. 1978;61:350-354.
45. Okahara K, Murakami T, Yamamoto S, Yata N. Skin microdialysis: detection of in vivo histamine release in cutaneous allergic reactions. Skin Pharmacol. 1995;8:113-118.
46. Bleehen SS, Thomas SE, Greaves MW, et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomised double- blind study. Br J Dermatol. 1987;117:81-88.
47. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A. 1986;83:4464-4468.
48. Schwartz LB. Mast cells and their role in urticaria. J Am Acad Dermatol. 1991;25:190-204.
49. Eady RAJ, Cowen T, Marshall TF, Plummer V, Greaves MW. Mast cell population density, blood vessel density and histamine content in normal human skin. Br J Dermatol. 1979;100:623-633.
50. Wiesner-Menzel L, Schulz B, Vakitzadeh F, Czarnetzki BM. Electron microscopical evidence for a direct contact between nerve fibres and mast cells. Acta Derm Venereol (Stockh). 1981;61:465-469.
51. Bienenstock J, Tomioka M, Matsuda H, et al. The role of mast cells in inflammatory processes: evidence for nerve/mast cell interactions. Int Arch Allergy Immunol. 1987;82:238-243.
52. Greaves MW, Shuster S. Responses of human skin blood vessels to bradykinin, histamine and 5-hydroxytryptamine. J Physiol. 1967;193:255-267.
53. Bradding P, Feather IH, Howarth PH, et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med. 1992;176:1381-1386.
54. Möller A, Lippert U, Lessmann D, et al. Human mast cells produce IL-8. J Immunol. 1993;151:3261-3266.
55. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. Human dermal mast cells contain and release tumor necrosis factor α which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci U S A. 1991;88:4220- 4224.
56. Bradding P, Roberts JA, Britten KM, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-α in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol. 1994;10:471- 480.
57. Okayama Y, Petit-Frére C, Kassel O, et al. IgE-dependent expression of mRNA for IL-4and IL-5 in human lung mast cells. J Immunol. 1995;155:1796-1808.
58. Bressler RB. Pathophysiology of chronic urticaria. Immunol Allergy Clin North Am. 1995;15:659-677.
59. Plaut M, Pierce JH, Watson CJ, Hanley-Hyde J, Nordan RP, Paul WE. Mast cell lines produce lymphokines in response to cross-linkage of FcεR1 or to calcium ionophores. Nature. 1989;339:64-67.
60. Selvan RS, Butterfield JH, Krangel MS. Expression of multiple chemokine genes by a human mast cell leukemia. J Biol Chem. 1994;269:13 893-13 898.
61. 4) in human skin. J Invest Dermatol. 1983;80:115-119.
62. Masinovsky B, Urdal D, Gallatin WM. IL-4 acts synergistically with IL-1β to promote lymphocyte adhesion to microvascular endothelium by induction of vascular cell adhesion molecule-1. J Immunol. 1990;145:2886-2895.
63. x-dependent alterations in leukocyte kinetics in vivo. Ciro Res. 1995;77:879-887.
64. Baggiolini M, Dahinden CA. CC cnemokines in allergic inflammation. Immunol Today. 1994;15:127-133.
65. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 1989;84:1045- 1049.
66. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol. 1990;145:3796-3806.
67. Coffman RL, Ohara J, Bond MW, Carty J, Ziotnik A, Paul WE. B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol. 1986;136:4538-4541.
68. Levi-Schaffer F, Segal V, Shalit M. Effects of interleukins on connective tissue type mast cells co-cultured with fibroblasts. Immunology. 1991;72:174-180.
69. Madden KB, Urban JF, Ziltener HJ, Schrader JW, Finkelman FD, Katona IM. Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis. J Immumol. 1991;147:1387-1391.
70. Tsuji K, Nakahata T, Takagi M, et al. Effects of interleukin-3 and interleukin-4 on the development of 'connective tissue-type' mast cells: interleukin-3 supports their survival and interleukin-4 triggers and supports their proliferation synergistically with interleukin-3. Blood. 1990;75:421-427.
71. Benyon RC, Robinson C, Church MK. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non- immunological stimuli. Br J Pharmacol. 1989;97:898-904.
72. Jorizzo JL, Coutts AA, Eady RAJ, Greaves MW. Vascular responses of human skin to injection of substance P and mechanism of action. Eur J Pharmacol. 1983;87:67-76.
73. Wallengren J, Håkanson R. Effects of substance P, neurokinin A and calcitonin gene-related peptide in human skin and their involvement in sensory nerve- mediated responses. Eur J Pharmacol. 1987;143:267-273.
74. Brain SD, Tippins JR, Morris HR, MacIntyre I, Williams TJ. Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol. 1986;87:533-536.
75. Castells MC, Irani A-M, Schwarte LB. Evaluation of human peripheral blood leukocytes for mast cell tryptase. J Immunol. 1987;138:2184-2189.
76. Valent P, Schmidt G, Besemer J, et al. Interleukin-3 is a differentiation factor for human basophils. Blood. 1989;73:1763-1769.
77. Ishizaka T, Mitsui H, Yanagicla M, Miura T, Dvorak AM. Development of human mast cells from their progenitors. Curr Opin Immunol. 1993;5:937-943.
78. Schroeder JT, MacGlashan OW, Kagey-Sobotka A, White JM, Lichtenstein LM. Cytokine generation by human basophils. J Allergy Clin Immunol. 1994;94:1189-1195.
79. Valent P. The phenotype of human eosinophils, basophils, and mast cells. J Allergy Clin Immunol. 1994;94:1177-1183.
80. Ochensberger B, Rihs S, Brumler T, Dahinden CA. IgE-independent interleukin-4 expression and induction of a late phase of leukotriene formation in human blood basophils. Blood. 1995;86:4039-4049.
81. Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen- induced rhinitis. N Engl J Med. 1985;313:65-70.
82. Shalit M, Schwartz LB, von Allmen C, Atkins PC, Lavker RM, Zweiman B. Release of histamine and tryptase during continuous and interrupted cutaneous challenge with allergen in humans. J Allergy Clin Immunol. 1990;86:117-125.
83. Malaviya R, Morrison AR, Pentland AP. Histamine in human epidermal cells is induced by ultraviolet light injury. J Invest Dermatol. 1996;106:785-789.
84. Kepley CL, Craig SS, Schwartz LB. Identification and partial purification of a unique marker for human basophils. J Immunol. 1995;154:6548-6555.
85. Greaves MW, Plummer VM, McLaughlan P, Stanworth DR. Serum and cell bound IgE in chronic urticaria. Clin Allergy. 1974;4:265-271.
86. Kern F, Lichtenstein LM. Defective histamine release in chronic urticaria. J Clin Invest. 1976;57:1369-1377.
87. Grattan GEH, Walpole DA, Dootson GM, Edler S, Francis DM, Corbett MF. Basophils in chronic urticaria. Clin Exp Dermatol. 1995;20:275-278.
88. Sutton BJ, Gould HJ. The human IgE network. Nature. 1993;336:421-428.
89. Lowman MA, Rees PH, Benyon RC, Church MK. Human mast cell heterogeneity: histamine release from mast cells dispersed from skin, lung, adenoids, tonsils, and colon in response to IgE-dependent and nonimmunologic stimuli. J Allergy Clin Immunol. 1988;81:590-597.
90. Grattan CEH, Wallington TB, Warin RP, Kennedy CTC, Bradfield JW. A serological mediator in chronic idiopathic urticaria: a clinical, immunological and histological evaluation. Br J Dermatol. 1986;114:583-590.
91. Kermani F, Niimi N, Francis DM, et al. Characterization of a novel mast cell- specific histamine releasing activity in chronic idiopathic urticaria (CIU). J Invest Dermatol. 1995;105:452.
92. Hide M, Francis DM, Grattan CEH, Barr RM, Winkelmann RK, Greaves MW. The pathogenesis of chronic idiopathic urticaria: new evidence suggests an autoimmune basis and implications for treatment. Clin Exp Allergy. 1994;24:624- 627.
93. Hide M, Francis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328:1599-1604.
94. Grattan CEH, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy. 1991;21:695-704.
95. Fiebiger E, Maurer D, Holub H, et al. Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin invest. 1995;96:2606- 2612.
96. Hide M, Francis DM, Barr RM, Greaves MW. Skin mast cell activation by autoantibodies in urticaria and therapeutic implications. In: Kitamura Y, Yamamoto S, Galli SJ, Greaves MW, eds. Biological and Molecular Aspects of Mast Cell and Basophil Differentiation and Function. New York, NY: Raven Press; 1995:183-192.
97. Fiebiger E, Wichlas S, Stingl G, Maurer D. Autoantibodies directed against FcεRIα: IgG subtype composition, prevalence, and disease specificity. J Invest Dermatol. 1996;107:492.
98. Tong LJ, Balakrishnan G, Kochan JP, Kinét JP, Kaplan AP. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol. 1997;99:461-465.
99. Zweiman B, Valenzano M, Atkins PC, Tanus T, Getsy JA. Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria. J Allergy Clin Immunol. 1996;98:89-98.
100. Nawata Y, Koike T, Hosokawa H, Tomioka H, Yoshida S. Anti-IgE autoantibody in patients with atopic dermatitis. J Immunol. 1985;135:478-482.
101. Marone G, Casolaro V, Paganelli R, Quinti I. IgG anti-IgE from atopic dermatitis induces mediator release from basophils and mast cells. J Invest Dermatol. 1989;93:246-252.
102. Grattan CEH, Francis DM, Slater NGP, Barlow RJ, Greaves MW. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet 1992;339:1078-1080.
103. O'Donnell BF, Barlow RJ, Kobza Black A, Greaves MW. Response of severe chronic urticaria to intravenous immunoglobulin (IVIG). Br J Dermatol. 1994;131 (suppl 44):23.
104. O'Donnell BF, O'Neill CM, Welsh KI, Barlow RJ, Kobza Slack A, Greaves MW. Is chronic urticaria an HLA-associated disease? Clin Exp Dermatol. 1995;20:271- 272.
105. O'Donnell BF, Swana GT, Kobza Black A, Greaves MW. Organ and non organ specific auto-immunity in chronic urticaria. Br J Dermatol. 1995;133(suppl 45): 42.
106. Barlow RJ, Kobza Black A, Greaves MW. Treatment of severe, chronic urticaria with cyclosporin A. Eur J Dermatol. 1993;3:273-275.
107. Haak-Frendscho M, Ridgway J, Shields R, Robbins K, German C, Jardieu P. Human IgE receptor a-chain IgG chimera blocks passive cutaneous anaphylaxis reaction in vivo. J Immunol. 1993;151;351-358.